Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

Article  CAS  PubMed  Google Scholar 

Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011;152:141–54.

Article  CAS  PubMed  Google Scholar 

Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Groger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988–1005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol. 2002;118:999–1010.

Article  CAS  PubMed  Google Scholar 

Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909–15.

Article  PubMed  Google Scholar 

Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells-the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells. 2001;19:1–11.

Article  CAS  PubMed  Google Scholar 

Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood. 1992;79:2370–7.

Article  CAS  PubMed  Google Scholar 

Secker KA, Keppeler H, Duerr-Stoerzer S, Schmid H, Schneidawind D, Hentrich T, et al. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9. Oncogene. 2019;38:7181–95.

Article  CAS  PubMed  Google Scholar 

Secker KA, Bloechl B, Keppeler H, Duerr-Stoerzer S, Schmid H, Schneidawind D, et al. MAT2A as key regulator and therapeutic target in MLLr leukemogenesis. Cancers. 2020;12:1342.

Article  PubMed  PubMed Central  Google Scholar 

Secker KA, Bruns L, Keppeler H, Jeong J, Hentrich T, Schulze-Hentrich JM, et al. Only hematopoietic stem and progenitor cells from cord blood are susceptible to malignant transformation by MLL-AF4 translocations. Cancers. 2020;12:1487.

Article  PubMed  PubMed Central  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

Article  CAS  PubMed  Google Scholar 

Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225–45.

Article  CAS  PubMed  Google Scholar 

Howell GJ, Holloway ZG, Cobbold C, Monaco AP, Ponnambalam S. Cell biology of membrane trafficking in human disease. Int Rev Cytol. 2006;252:1–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang F, Dai X, Wang Y. 5-Aza-2’-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis. Mol Cell Proteom. 2012;11:M111 016915.

Article  Google Scholar 

Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, et al. 2-Hydroxypropyl-beta-cyclodextrin acts as a novel anticancer agent. PLoS ONE. 2015;10:e0141946.

Article  PubMed  PubMed Central  Google Scholar 

Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood. 2004;104:1816–24.

Article  CAS  PubMed  Google Scholar 

Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A, et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia. 2000;14:1444–50.

Article  CAS  PubMed  Google Scholar 

Casalou C, Costa A, Carvalho T, Gomes AL, Zhu Z, Wu Y, et al. Cholesterol regulates VEGFR-1 (FLT-1) expression and signaling in acute leukemia cells. Mol Cancer Res. 2011;9:215–24.

Article  CAS  PubMed  Google Scholar 

Usman H, Ameer F, Munir R, Iqbal A, Zaid M, Hasnain S, et al. Leukemia cells display lower levels of intracellular cholesterol irrespective of the exogenous cholesterol availability. Clin Chim Acta. 2016;457:12–7.

Article  CAS  PubMed  Google Scholar 

Vitols S, Angelin B, Ericsson S, Gahrton G, Juliusson G, Masquelier M, et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci USA. 1990;87:2598–602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–30.

Article  CAS  PubMed  Google Scholar 

Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331–40.

Article  CAS  PubMed  Google Scholar 

Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160–4.

Article  CAS  PubMed  Google Scholar 

Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101:3628–34.

Article  CAS  PubMed  Google Scholar 

van der Weide K, de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009;15:3076–83.

Article  PubMed  Google Scholar 

van der Weide K, Korthuis PM, Kuipers F, de Vries EG, Vellenga E. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. Leukemia. 2012;26:845–8.

Article  PubMed  Google Scholar 

Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007;109:2999–3006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, et al. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leuk Res. 2018;67:17–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138:499–508.

Article  CAS  PubMed  Google Scholar 

Bjarnadottir O, Kimbung S, Johansson I, Veerla S, Jonsson M, Bendahl PO, et al. Global transcriptional changes following statin treatment in breast cancer. Clin Cancer Res. 2015;21:3402–11.

Article  CAS  PubMed  Google Scholar 

Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood. 2010;115:4787–97.

Article  CAS  PubMed  Google Scholar 

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, et al. Corrigendum: ROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016;22:692.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou H, Yang N, Zhang X, Chen HW. RORgamma is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. Biochem Pharmacol. 2022;196:114725.

Article  CAS  PubMed  Google Scholar 

Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, et al. RORgamma is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat Commun. 2019;10:4621.

Article  PubMed  PubMed Central  Google Scholar 

Yang N, Yang Y, Huang Z, Chen HW. Deregulation of cholesterol homeostasis by a nuclear hormone receptor crosstalk in advanced prostate cancer. Cancers. 2022;14:3110.

Article  PubMed  PubMed Central  Google Scholar 

Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sonderby CK, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44:D917–24.